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Abstract
Background: In addition to their well-documented ocular therapeutic effects, glucocorticoids
(GCs) can cause sight-threatening side-effects including ocular hypertension presumably via
morphological and biochemical changes in trabecular meshwork (TM) cells. In the present study,
we directly compared the glucocorticoid receptor (GR) potency for dexamethasone (DEX),
fluocinolone acetonide (FA) and triamcinolone acetonide (TA), examined the expression of known
GRα and GRβ isoforms, and used gene expression microarrays to compare the effects of DEX, FA,
and TA on the complete transcriptome in two primary human TM cell lines.
Methods: GR binding affinity for DEX, FA, and TA was measured by a cell-free competitive radio-
labeled GR binding assay. GR-mediated transcriptional activity was assessed using the GeneBLAzer
beta-lactamase reporter gene assay. Levels of GRα and GRβ isoforms were assessed by Western
blot. Total RNA was extracted from TM 86 and TM 93 cells treated with 1 μM DEX, FA, or TA
for 24 hr and used for microarray gene expression analysis. The microarray experiments were
repeated three times. Differentially expressed genes were identified by Rosetta Resolver Gene
Expression Analysis System.
Results: The GR binding affinity (IC50) for DEX, FA, and TA was 5.4, 2.0, and 1.5 nM, respectively.
These values are similar to the GR transactivation EC50 of 3.0, 0.7, and 1.5 nM for DEX, FA, and
TA, respectively. All four GRα translational isoforms (A-D) were expressed in TM 86 and TM 93
total cell lysates, however, the C and D isoforms were more highly expressed relative to A and B.
All four GRβ isoforms (A-D) were also detected in TM cells, although GRβ-D isoform expression
was lower compared to that of the A, B, or C isoforms. Microarray analysis revealed 1,968 and
1,150 genes commonly regulated by DEX, FA, and TA in TM 86 and TM 93, respectively. These
genes included RGC32, OCA2, ANGPTL7, MYOC, FKBP5, SAA1 and ZBTB16. In addition, each
GC specifically regulated a unique set of genes in both TM cell lines. Using Ingenuity Pathway
Analysis (IPA) software, analysis of the data from TM 86 cells showed that DEX significantly
regulated transcripts associated with RNA post-transcriptional modifications, whereas FA and TA
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modulated genes involved in lipid metabolism and cell morphology, respectively. In TM 93 cells,
DEX significantly regulated genes implicated in histone methylation, whereas FA and TA altered
genes associated with cell cycle and cell adhesion, respectively.
Conclusion: Human trabecular meshwork cells in culture express all known GRα and GRβ
translational isoforms, and GCs with similar potency but subtly different chemical structure are
capable of regulating common and unique gene subsets and presumably biologic responses in these
cells. These GC structure-dependent effects appear to be TM cell-lineage dependent.
Background
Glucocorticoid (GC) therapy can lead to the development
of glaucomatous ocular hypertension and secondary
open-angle glaucoma that is clinically similar to primary
open-angle glaucoma [1]. The elevated intraocular pres-
sure (IOP) is due to increased aqueous humor outflow
resistance and is associated with morphological and bio-
chemical changes in the trabecular meshwork (TM) [2].
These changes are associated with increased deposition of
extracellular matrix material in the outflow pathway [3],
which may be due, in part, to an inhibition of TM phago-
cytosis [4], decreased extracellular activity of stromelysin
and tissue plasminogen activator [5], alteration of the
actin cytoskeleton [6] and formation of intercellular junc-
tions [7]. Most of the effects of GCs on TM cells and tis-
sues are likely due to GC-mediated TM cell gene
expression, including the induction of myocilin, serum
amyloid A1, α A-crystallin, insulin growth factor binding
protein 2, growth arrest-specific 1 and other genes [8-13].
It is currently unclear which genes or combinations of
genes are modulated by GCs and ultimately lead to
increased IOP.
The biological actions of glucocorticoids are mediated
through the cytoplasmic glucocorticoid receptor (GR),
which belongs to the nuclear receptor subfamily that
includes receptors for mineralocorticoids, estrogen and
thyroid hormones, retinoic acid, and vitamin D [14].
Upon hormone binding, the activated ligand-bound
receptor translocates into the nucleus and binds as a
homodimer to glucocorticoid response elements within
the promoter region of target genes. The GR can positively
or negatively regulate gene expression, depending on the
response element sequence and promoter context. The GR
also modulates gene expression, independent of glucocor-
ticoid response elements, by physically interacting with
other transcription factors (e.g., activating protein AP-1
and nuclear factor NF-κB) [15].
GRα and GRβ are the two major splice variants of GR as a
result of alternative splicing. The GRβ isoform acts as a
natural dominant negative inhibitor of GRα-induced
transactivation of glucocorticoid-responsive genes [16].
Amino acid sequence analysis revealed that GRα and GRβ
isoforms are identical from the amino terminus to amino
acid 727 but diverge beyond this position, with GRα hav-
ing an additional 50 amino acids and GRβ having an
additional, non homologous, 15 amino acids. The expres-
sion of both GRα and GRβ was reported in cultured
human TM cells [17,18].
Recent evidence indicates that at least eight different GRα
or GRβ N-terminal isoforms are generated from one single
GR gene by alternative translation initiation [19]. For
GRα, receptor isoforms are designated GRα-A, -B, -C1, -
C2, -C3, -D1, -D2 and -D3 [20]. The GRα-A isoform is the
full-length receptor containing amino acids 1-777. The
other GRα isoforms have shortened N termini. The appar-
ent molecular weights for GRα-A, -B, -C and -D are 94, 91,
82-84 and 53-56 KDa, respectively. All GRα isoforms are
functional receptors and contain the identical intact lig-
and-binding domain that binds GCs. The GRα isoforms
transcriptionally regulate common and unique sets of
genes within the context of a single cell type [20]. Further-
more, the tissue expression patterns of GRα translational
isoforms have been determined in both rats and mice and
the levels of the GRα isoforms differ widely among tissues
[20]. Thus, the unique transcriptional activities and dis-
tinct tissue-specific distribution patterns of GRα isoforms
could provide a novel mechanism for tissue-specific glu-
cocorticoid responses. Further studies are needed to con-
firm this in human tissues. For GRβ, receptor isoforms are
designated GRβ-A, -B, -C1, -C2, -C3, -D1, -D2 and -D3
[19]. The GRβ-A isoform is the full-length receptor con-
taining amino acids 1-742 with an apparent molecular
weight of 90 KDa. The other GRβ isoforms have shortened
N termini. Although little is known about the transcrip-
tional activity and tissue distribution of GRβ isoforms,
Fruchter et al demonstrated that the potency of the domi-
nant negative effect of GRβ on GRα-induced transactiva-
tion depends on both the type and the dose of the
synthetic glucocorticoids in use [16].
Recently, Schaaf et al showed that the intranuclear distri-
bution and mobility of the GR is highly dependent on the
chemical structure of the glucocorticoid with which it is
associated [21]. Some ligands, especially high-affinity syn-
thetic ligands like dexamethasone and triamcinolone ace-
tonide, induce a highly punctate GC-GRα distribution
organized in discrete domains of high receptor concentra-BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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tion. In contrast, other ligands, mainly naturally occurring
low-affinity ligands like cortisone and cortexolone,
induce a more homogeneous, although still not entirely
random, distribution. More importantly, structure-func-
tion analysis revealed that the 9-fluoro and 17-hydroxy
groups on the steroid significantly impact nuclear receptor
distribution. The effects of GC-mediated GR nuclear dis-
tribution and mobility patterns on GR-dependent tran-
scriptional activity are still unclear.
Microarray technology provides a comprehensive, rapid
and efficient method for large scale profiling of gene
expression changes in biological samples (e.g., treatment
versus control, disease versus normal). The advantages of
DNA microarray technology include the ability to analyze
expression patterns of thousands of genes simultaneously.
Other advantages include the ability to characterize rela-
tionships between genes and the changes in biological
processes such as disease states, developmental stages and
responses to drugs [22,23]. More importantly, Canales et
al recently showed that results generated from five differ-
ent microarray platforms correlated exceedingly well with
real-time quantitative polymerase chain reaction (RT-
PCR), as well as other non-microarray-based approaches
to determine transcript abundance [24].
In this study, using two primary human TM cell lines iso-
lated from either a newborn or an adult donor, we exam-
ined the distribution of GRα and GRβ isoforms and
determined global gene expression profiles after treat-
ment with 1 μM of three potent GR agonists (dexametha-
sone, fluocinolone acetonide and triamcinolone
acetonide). TM 86 and TM 93 expressed all known GRα
and GRβ isoforms as determined by Western blot. The
gene expression profiles and Ingenuity Pathway Analysis
demonstrated that each of the three GCs regulated a com-
mon and unique subset of genes that is associated with a
cell lineage-dependent specific signaling pathway.
Methods
Cell culture and glucocorticoid treatment conditions
Human primary cultures of trabecular meshwork cells,
TM 86 and TM 93, were established and characterized
from 3-month- and 35-year-old human eye donors,
respectively, according to original methods [25]. Cells
were maintained in low glucose Dulbecco's Modified
Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supple-
mented with 10% (vol/vol) FBS (American Type Culture
Collection, Manassas, VA), 1% (vol/vol) penicillin and
streptomycin (Invitrogen). Cells from the human HeLa
cervical adenocarcinoma cell line (American Type Culture
Collection) were maintained in α-MEM medium supple-
mented with 10% (v/v) FBS, 1% (v/v) penicillin and
streptomycin. All cells were used within passages 3 to 6.
For treatment with DEX, FA, or TA, TM cells were grown in
100-mm tissue culture plates (BD Labware, Bedford, MA)
in DMEM complete medium until reaching 100% conflu-
ence. Cells were maintained for one week with medium
renewal every other day. The day before the experiment,
confluent TM were washed once with phosphate-buffered
saline (PBS) and then the cells were maintained in 1%
FBS-containing medium with antibiotics. Cells were
treated with 1 μM of DEX, FA, or TA for an additional 24
hr. Control cells were treated with 0.1%(v/v) dimethylsul-
foxide (DMSO). At the end of GC treatment, supernatant
was discarded and the cell monolayer was kept frozen at -
80°C for subsequent total RNA extraction and gene
expression profiling.
Glucocoroticoid receptor binding affinity
GR binding affinity assay was performed at Cerep Inc.
(Celle l'Evescault, France), according to an established
method [26]. Brifely, fractions of IM-9 human B lym-
phoblast cell cytosol (300 μg proteins) are incubated for 6
h at 4°C with 1.5 nM [3H]dexamethasone in the absence
or presence of DEX, FA, or TA in a buffer containing 10
mM Tris ethanesulfonic acid-NaOH (pH 7.4), 1 mM
EDTA, 10 mM Na2MoO4, 20 mM β-mercaptoethanol and
10% glycerol. Nonspecific binding is determined in the
presence of 10 μM triamcinolone. Following incubation,
the samples are filtered rapidly under vacuum through
glass fiber filters (GF/B, Packard) presoaked with 0.3%
Poly(ethyleneimine) and rinsed several times with ice-
cold 50 mM Tris-HCl using a 96-sample cell harvester
(Unifilter, Packard). The filters are dried and counted for
radioactivity in a scintillation counter (Topcount, Pack-
ard) using a scintillation cocktail (Microscint 0, Packard).
The results are expressed as percent inhibition of the con-
trol radioligand specific binding. The IC50 values (concen-
tration causing half-maximal inhibition of control
specific binding) and Hill coefficients (nH) were deter-
mined by non-linear regression analysis of the competi-
tion curves generated with mean replicate values using
Hill equation curve fitting (Y = D + [(A - D)/(1 + (C/
C50)nH)], where Y = specific binding, D = minimum spe-
cific binding, A = maximum specific binding, C = com-
pound concentration, C50 = IC50, and nH = slope factor).
This analysis was performed using the Hill software
(Cerep) and validated by comparison with data generated
by the commercial software SigmaPlot® 4.0 for Windows®
(© 1997 by SPSS Inc.). The inhibition constants (Ki) were
calculated using the Cheng Prusoff equation (Ki = IC50/
(1+(L/KD)), where L = concentration of radioligand in the
assay, and KD = affinity of the radioligand for the recep-
tor). The standard reference compound is DEX, which is
tested in each experiment at several concentrations to
obtain a competition curve from which an IC50 is calcu-
lated. The GR binding assay was performed in duplicate.BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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Glucocoroticoid receptor-mediated transactivation
GR transactivation activity was assessed by the Invitrogen
SelectScreen Profiling Service (Madison, WI), using Invit-
rogen GeneBLAzer beta-lactamase reporter gene technol-
ogy [27]. Profiling was performed using human HeLa cells
stably transfected with an expression construct containing
β-lactamase cDNA under the control of the MMTV
response element previously identified as a GR response
element (MMTV-bla HeLa CellSensor®). The MMTV-bla
HeLa cells were plated in 384-well plates in 32 μl assay
medium (OPTIMEM + 1% charcoal/dextran stripped FBS)
at a density of 10,000 cells/well and incubated overnight.
After addition of 8 μl of a 5-fold concentrated compound
solution (DEX, FA, or TA) in assay medium, the cells were
incubated for additional 5 hr. The 5 hr time point was
chosen based on preliminary results showing that the
optimal DEX-mediated transcriptional activation of GR
occurred between 5 and 16 hr. The β-lactamase activity of
each sample was determined by adding 8 μl of 6-fold con-
centrated LiveBLAzer™ substrate solution to the samples
followed by two hours of incubation at room temperature
in a Tecan Safire2 plate reader using the appropriate Live-
BLAzer™ filter settings. GC treatment was performed in
15-point dose response using a three-fold dilution series
starting with a maximum compound concentration of 10
μM. Each data point represents a triplicate sample (n = 3).
Assay reproducibility was determined by calculating Z'
values for untreated vs. maximum stimulation. The Gene-
BLAzer assay was performed twice.
Distribution of glucocoroticoid receptor isoforms in TM 86 
and TM 93 cells
TM cells were grown in 100-mm tissue culture plates (BD
Labware) in DMEM complete medium until reaching
100% confluence. Cells were then maintained for one
week with medium renewal every other day. Human HeLa
cells were used as a positive control in these experiments.
The day before the experiment, confluent TM and HeLa
cells were washed once with phosphate-buffered saline
(PBS) and stepped to 1% FBS-containing medium with
antibiotics. After 24 hr, cells were washed twice with ice-
cold PBS and lysed in 400 μL radioimmuno-precipitation
assay buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl,
0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA; Upstate
Biotech, Lake Placid, NY), supplemented with 0.2%
sodium dodecyl sulfate (SDS) and a 1% (vol/vol) cocktail
of protease inhibitors, serine-threonine phosphatase
inhibitors, and tyrosine phosphatase inhibitors (Sigma-
Aldrich, Saint Louis, MO). After 30 min incubation on ice,
the lysates were centrifuged at 14,000 rpm for 20 min at
4°C. Supernatants were transferred to clean microfuge
tubes, and the total protein concentration of each sample
was measured with a bicinchoninic acid protein assay
(Pierce Biotechnology, Rockford, IL). Cell lysates (45 μg
protein) in SDS sample buffer were separated on 7% Tris-
acetate gel by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes. Four GRα iso-
forms were detected by a specific polyclonal antibody
anti-GRα (PA1-516) from ABR Affinity BioReagents
(Golden, CO), whose epitope corresponds to the specific
GRα peptide segment aa 755-771 [20]. Four GRβ iso-
forms were detected by a specific polyclonal antibody
anti-GRβ (PA3-514) from ABR Affinity BioReagents,
whose epitope corresponds to the specific GRβ peptide
segment aa 728-742 [19]. Protein bands were visualized
with a chemiluminescence detection kit (Invitrogen).
Three independent cell lysate samples were tested per cell
line for each antibody.
RNA isolation and gene expression profiling
RNA isolation and gene expression profiling were per-
formed at Cogenics™, A Division of Clinical Data® (Mor-
risville, NC), using methods that have been previously
described [28-31]. Briefly, RNA was isolated from flash
frozen cell culture plates using RNeasy Mini columns
(Qiagen, Valencia, CA) according to the manufacturer's
protocol. There were three biological replicates per treat-
ment condition. The quantity and purity of the extracted
RNA was evaluated using a NanoDrop ND-1000 spectro-
photometer (Nanodrop Technologies, Wilmington, DE,
USA) and its integrity measured using an Agilent Bioana-
lyzer. For microarray hybridizations, 500 ng of total RNA
from each RNA sample was amplified and labeled with a
fluorescent dye (Cy3) using the Low RNA Input Linear
Amplification Labeling kit (Agilent Technologies, Palo
Alto, CA, USA) following the manufacturer's protocol.
The amount and quality of the fluorescently labeled cRNA
was assessed using a NanoDrop ND-1000 spectropho-
tometer and an Agilent Bioanalyzer. An equal amount of
Cy3-labeled cRNA (1.6 μg) was hybridized to the Agilent
Human Whole Genome Oligo Microarray (Agilent Tech-
nologies) for 17 hours, prior to washing and scanning.
Data were extracted from scanned images using Agilent's
Feature Extraction Software (Agilent Technologies) using
default settings. Gene expression data were loaded into
the Rosetta Resolver® Gene Expression Analysis System
version 7.1.0.1.11. Data from three biological replicate
hybridizations were combined using an error-weighted
average and the following criteria was used to identify dif-
ferentially expressed transcripts: a log ratio p-value <
0.001, and a log(10) intensity measurement > -1.8. The
full complement of microarray data has been deposited in
the NIH/NLM Gene Expression Omnibus (GEO accession
# GSE16643) [32].
Gene ontology enrichment analysis was performed on
lists of differentially expressed transcripts using the High-
Throughput GoMiner integrative gene ontology tool with
a significance threshold of an enrichment p-value < 0.01
[33,34]. The lists of differentially expressed genes wereBMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
Page 5 of 14
(page number not for citation purposes)
also applied to global functional, network and canonical
pathway analyses using Ingenuity Pathway Analysis (Inge-
nuity® Systems, Redwood City, CA). In order to identify
the most significant results in IPA's analyses, the Ben-
jamini-Hochberg multiple-testing corrected p-value was
used with a significance threshold of 0.05.
Results
Glucocorticoid receptor binding affinity
The GR binding affinity for DEX, FA and TA has never
been directly compared in one cell type. Moreover, a wide
range of GR binding affinities have been reported in the
literature for each of these three GCs [35]. Therefore, we
sought to directly compare the GR binding affinity in vitro
using a GR radiolabeled competitive binding assay
(Cerep, France). The results are shown in Table 1. The IC50
values for DEX, FA, and TA were 5.4, 2.0, and 1.5 nM,
respectively. These results suggest that the GR binding
affinities for these three drugs are roughly equivalent.
Interestingly, the GR binding affnitiy of 5 nM for DEX in
IM-9 cells is consistent with previously reported cellular
binding affinity of DEX in primary human TM cells [18].
The distribution of GRα isoforms in human IM-9 cells
used in the GR binding affinity assay is unknown. Since
different GRα isoforms might exhibit different binding
affinities for each GC, the observed GR binding affinity is
likely an aggregate affinity generated by multiple GR iso-
forms.
Glucocorticoid receptor transactivation potency
The GR transactivation potency for DEX, FA and TA has
never been directly compared in one cell type. Moreover,
a wide range of GR transactivation potency values have
been reported in the literature for each of these three GCs
[35]. Therefore, GR transactivation potency was assessed
in the GeneBLAzer β-lactamase reporter gene technology
in MMTV-bla HeLa CellSensor®  cells (Invitrogen).
Attempts to establish a robust and reproducible Gene-
BLAzer assay using primary human TM cells failed, and
HeLa cells seemed a reasonable surrogate since the levels
of all GRα and GRβ isoforms in these cells were compara-
ble to those in TM 86 and TM 93 cells (Figure 1). HeLa
cells were treated with various concentrations of GC for 5
hr. Figure 2 shows that all three GCs induced an increase
in GR transactivation activity in a dose-dependent man-
ner. The EC50  (concentration causing a half-maximal
increase in GR transactivation) values for DEX, FA, and
TA, were 3.02 ± 0.02, 0.67 ± 0.10, and 1.29 ± 0.28 nM,
respectively. These data suggest that all three GCs are
roughly equivalent at stimulating GR transcriptional
activity. The expression of multiple GRα isoforms in HeLa
cells has been previously reported [20] and confirmed in
our study. Assuming that different GRα isoforms might
exhibit different transcriptional activities in response to
each GC, the observed GR-mediated transactivation func-
tion is the aggregate response generated by multiple GR
isoforms in these cells.
GRα and GRβ isoform expression in TM 86 and TM 93 
cells
Levels of total GRα and total GRβ proteins have been pre-
viously reported in human TM by competitive binding
assay [18] or Western blot [17]. However, to our knowl-
edge, the expression of GRα and GRβ translational iso-
forms in human TM cells has never been determined. The
distribution of four GRα isoforms, GRα-A, GRα-B, GRα-
C, and GRα-D was assessed in TM 86 and TM 93 total cell
lysates by Western blot using a specific anti-GRα anti-
body. Western blots showed that both TM 86 and TM 93
expressed all four known GRα isoforms (Figure 1A).
Higher levels of GRα-C and GRα-D isoforms were
observed compared to GRα-A and GRα-B. The additional
bands in between GRα-C and GRα-D isoforms may be
degradation products or cell-specific isoforms. The distri-
bution of four GRβ isoforms, GRβ-A, GRβ-B, GRβ-C, and
GRβ-D was also determined in TM 86 and TM 93 total cell
lysates by Western blot using a specific anti-GRβ antibody.
Figure 1B shows that both TM 86 and TM 93 expressed all
four known GRβ isoforms. The level of GRβ-D isoform
was lower when compared to levels of GRβ-A, GRβ-B, and
GRβ-C in both TM 86 and TM 93 cells. Moreover, TM 93
expressed lower levels of GRβ-D as compared to that in
TM 86. The additional bands in between GRβ-C and GRβ-
D isoforms may be degradation products or cell-specific
isoforms.
Gene expression profiles for DEX, FA, and TA in TM 86 and 
TM 93 cells
The chemical structures of DEX, FA, and TA are shown in
Figure 3. To determine the biological impact of GC struc-
ture on GR transcription, primary TM 86 and TM 93 cells
Table 1: Glucocorticoid receptor binding affinity for 
dexamethasone, fluocinolone acetonide, and triamcinolone 
acetonide.
Ligand IC50
(nM)
Ki
(nM)
nH
Dexamethasone 5.36 ± 1.13 2.68 ± 0.58 1.06 ± 0.18
Fluocinolone acetonide 2.00 ± 0.42 0.97 ± 0.17 1.10 ± 0.00
Triamcinolone acetonide 1.45 ± 0.50 0.72 ± 0.24 1.05 ± 0.07
IC50, Ki, and nH values were determined using a glucocorticoid 
receptor radiolabeled competition binding assay as described in 
"Materials and methods" section.
Data shown for dexamethasone are averages of fourteen independent 
experiments performed in triplicate ± SD.
Data shown for fluocinolone acetonide and triamcinolone acetonide 
are averages of two independent experiments performed in triplicate 
± SD.BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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Western blot analysis of the GRα (A) and GRβ (B) isoforms in human TM86 and TM93 Figure 1
Western blot analysis of the GRα (A) and GRβ (B) isoforms in human TM86 and TM93. Blots resolving 45 μg of 
total cell lysates from HeLa, TM 86, or TM 93 cells detected with anti-GRα antibody (PA1-516) or anti-GRβ antibody (PA3-
514) are shown. Three independent cell lysates were analyzed per cell line. Additional bands in between GR-C and GR-D iso-
forms may be degradation products or cell-specific isoforms.
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Activation of glucocorticoid receptor in response to dexam- ethasone, fluocinolone acetonide and triamcinolone aceto- nide Figure 2
Activation of glucocorticoid receptor in response to 
dexamethasone, fluocinolone acetonide and triamci-
nolone acetonide. MMTV-bla Hela CellSensor® cells were 
treated with GC for 5 hr. β-lactamase reporter gene activity 
was assessed by adding the LiveBLAzer substrate solution for 
2 hr. Each data point represents a triplicate sample from two 
independent experiments. Results are plotted as a response 
ratio (normalized against untreated values).
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Structures of dexamethasone, fluocinolone acetonide, and  triamcinolone acetonide Figure 3
Structures of dexamethasone, fluocinolone aceto-
nide, and triamcinolone acetonide.BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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were treated with DEX, FA, TA, or a vehicle control and
total RNA was isolated 24 hr later followed by gene
expression profiling using Agilent Whole Human
Genome Microarrays. The saturating concentration of 1
μM for each GC was chosen based on the GeneBLAzer
reporter gene assay results (Figure 2) and human clinical
reports showing ocular tissue concentrations for DEX or
TA >1 μM following local administration [36,37]. Three
biological replicates were analyzed using independent
microarrays for each drug treatment that were then
directly compared to vehicle controls (0.1% DMSO).
Since TM 86 and TM 93 cells were isolated from donors of
different ages, all subsequent microarray data analysis
were performed for each TM cell type, separately [for com-
plete gene lists see additional file 1]. There were 1968
genes regulated by all three GCs in TM 86 cells (Figure
4A). However, the total number of genes uniquely regu-
lated by each GC varies: 1761, 693, or 388 for DEX, FA, or
TA, respectively, suggesting a potential transcriptional
mechanism underlying the different cellular responses to
each of the GCs (Figure 4A). In TM 93 cells, 1150 genes
were regulated commonly by all three GCs (Figure 4B).
Each of the GCs also regulated a unique set of genes in TM
93 cells. There were 745, 2294, or 555 genes regulated
uniquely by DEX, FA, or TA, respectively (Figure 4B).
Table 2 summarizes the top 24 genes regulated by DEX,
FA or TA in TM 86 cells based on the magnitude of fold
change. These genes included RGC32, ANGPTL7, MYOC,
FKBP5, SAA1, MXRA5, PER3 and AQP1. Interestingly,
OCA2 and PF4 were found to be uniquely upregulated by
70.2- or 3.1-fold in response to DEX or FA, respectively.
Table 3 shows the 24 genes most highly upregulated by
DEX, FA or TA in TM 93 cells. The list of genes included
OCA2, SAA1, ANGPTL7, FKBP5, MYOC, AQP1, MXRA5
and PER3. Similar to TM 86, SLP1 was found to be
uniquely upregulated by 18.0-fold in response to FA.
Gene function analysis
Using Ingenuity Pathway Analysis, we identified networks
that were significantly enriched using the lists of differen-
tially expressed genes. This analysis confirmed the unique
regulation of a functional subset of genes by each of the
GCs in TM 86 and TM 93 cells. For example, in TM 86,
DEX significantly regulated a network centered around
the RNA binding protein S1 or RNPS1 (Figure 5), whereas
FA significantly modulated a GR-dependent network
(data not shown). In TM 93, DEX significantly affected a
network centered around a histone methyltransferase
known as suppressor of zeste 12 homolog or SUZ12 (data
not shown), whereas FA regulated a transcriptional repres-
sor referred to as jumonji, AT rich interactive domain 1B
or JARID1B-based network (Figure 6).
Using the High-Throughput GoMiner integrative gene
ontology tool, the enrichment of biological themes from
the differentially expressed transcript lists in response to
each of the GCs was also evaluated in both TM 86 and TM
93 cell lines [for complete biological processes lists see
Venn diagrams showing the distribution and overlap of differentially expressed genes in TM 86 (A) and TM 93 (B) cells Figure 4
Venn diagrams showing the distribution and overlap of differentially expressed genes in TM 86 (A) and TM 93 
(B) cells. TM cells were treated with dexamethasone, fluocinolone acetonide, or triamcinolone acetonide at 1 μM for 24 hr. 
The two criteria for the identification of significantly different gene expression were log ratio p < 0.001 and log (10) intensity 
measurement >-1.8.
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additional files 2, 3, 4, 5, 6, 7, 8 and 9]. This analysis con-
firmed again that each of the GCs can generate both a
common and unique pattern of gene expression that is
associated with specific biological processes. Results
showed that in TM 86 cells, DEX significantly regulated
cellular component organization and biogenesis, whereas
FA and TA regulated actin filament-based process and
mitotic cell cycle, respectively. In TM 93 cells, DEX signif-
icantly regulated membrane lipid metabolic process,
whereas FA and TA regulated biopolymer metabolic proc-
ess and smooth muscle cell proliferation, respectively.
Discussion
The goals of this study were to measure GR potency for
three GCs used to treat inflammatory eye disease, examine
the expression of GRα and GRβ translational isoforms in
human TM cells, and to assess changes in mRNA levels in
TM cells treated with DEX, FA or TA. The findings of this
study demonstrate that TM cells in vitro express all GRα
and GRβ N-terminal isoforms, and that GCs with dissim-
ilar structures but similar GR potency are capable of regu-
lating common and unique subsets of genes and
biological networks that appear to be cell-lineage depend-
ent.
Before characterizing GC transcript responses in TM cells,
we deemed it important to directly measure and compare
the GR binding affinity for DEX, FA, and TA, and their
potency in a GR-mediated transactivation assay. The GR
binding affinities for all three GCs were in the low nM
range and were considered roughly equivalent. Impor-
tantly, the GR binding affinity of 5 nM for DEX reported
here in IM-9 B-lymphoblastoid cells is identical to that
reported in primary human TM cells [18]. The EC50 values
for DEX, FA, and TA in the GR-mediated HELA cell trans-
activation assay were also in the low nM range. These data
support the notion that these three GCs are roughly equiv-
alent at stimulating GR-mediated transcriptional activity
[16]. The relationship between receptor potency and GR
translational isoform expression is to date poorly under-
stood. The expression of GRα isoforms in HeLa cells has
been previously reported [20] and confirmed in our study,
Table 2: Top 24 differentially regulated genes in response to DEX, FA, or TA treatment in TM 86 cell line. 
Gene Symbol Gene Name GenBank Accession Number DEX
FC
FA
FC
TA
FC
UPREGULATED
RGC32 Response gene to complement 32 NM_014059 >100 >100 >100
OCA2 oculocutaneous albinism II NM_000275 70.2 NS NS
SAA1 Serum amyloid A1 NM_000331 30.9 34.6 35.3
ANGPTL7 Angiopoietin-like 7 NM_021146 24.8 16.0 26.5
ITGA10 Integrin, alpha 10 NM_003637 22.4 25.1 17.7
LSP1 clone pp9372 unknown mRNA AF289610 20.9 14.9 15.4
KCNB1 Potassium voltage-gated channel, Shab-related subfamily, 
member 1
NM_004975 13.6 20.1 19.9
FKBP5 FK506 binding protein 5 NM_004117 12.9 13.8 12.5
KLF15 Kruppel-like factor 15 NM_014079 12.5 11.5 11.1
ANGPTL4 Angiopoietin-like 4 NM_139314 7.0 9.6 7.9
MYOC Myocilin, trabecular meshwork inducible glucocorticoid 
response
NM_000261 7.5 7.4 6.7
ZBTB16 Zinc finger and BTB domain containing 16 NM_006006 7.5 8.7 8.1
PF4 platelet factor 4 (chemokine (C-X-C motif) ligand 4) NM_002619 NS 3.2 NS
DOWNREGULATED
KAL1 Kallmann syndrome 1 sequence NM_000216 -5.8 -5.6 -6.7
GABRB1 Gamma-aminobutyric acid (GABA) A receptor, beta 1 NM_000812 -6.9 -4.0 -4.9
MXRA5 Matrix-remodelling associated 5 NM_015419 -6.0 -4.3 -5.4
PER3 Period homolog 3 (Drosophila) NM_016831 -5.1 -5.3 -7.0
AQP1 Aquaporin 1 (Colton blood group) NM_198098 -5.5 -4.4 -5.1
PCDH19 Protocadherin 19 NM_020766 -4.7 -5.1 -5.0
RASL11B RAS-like, family 11, member B NM_023940 -4.0 -4.9 -4.0
KIF4A Kinesin family member 4A NM_012310 -4.0 -3.6 -4.1
CXADR Coxsackie virus and adenovirus receptor NM_001338 -4.7 -3.4 -4.8
CCRL1 Chemokine (C-C motif) receptor-like 1 NM_178445 -3.8 -4.7 -3.4
ENST00000344214 Unknown Unknown NS NS -3.1
FC: fold change; NS: not significant
The genes are listed according to their rank order fold-change.BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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however, the distribution of GRα isoforms in human IM-
9 cells used in the GR binding affinity assay is unknown.
Assuming that different GRα isoforms may exhibit differ-
ent binding affinities for each GC, the observed GR bind-
ing affinity or transactivation potency is the aggregate
affinity or potency generated by multiple GR isoforms in
these cells. To avoid possible subtle but significant differ-
ences in GC potencies in TM cells, we chose a saturating
GC dose of 1 μM in subsequent gene regulation studies.
Recently, Lu and Cidlowski showed distinct tissue-specific
distribution patterns of N-terminal GRα isoforms in mice
and rat tissues, and suggested that unique GRα transcrip-
tional activities and distinct tissue-specific distribution
patterns could provide a novel mechanism for tissue-spe-
cific glucocorticoid responses [20]. Total GRα and GRβ
protein expression was previously reported in human TM
by a competitive binding assay [18] or by Western blot
[17]. Our results show that TM 86 and TM 93 cells express
detectable levels of all known GRα or GRβ isoforms (A-
D). To our knowledge, this is the first report of GRα and
GRβ translational isoforms in human TM cells. Although
the relationship between GC-mediated biological
responses and the distribution of GRα and GRβ isoforms
in TM cells is currently undefined, it is tempting to specu-
late that GRα-C may play an important role in TM cells
since it was shown that this isoform has the highest rela-
tive transcriptional activity in response to DEX [20].
Gene expression profiling studies using Agilent microar-
ray revealed that the two primary TM cell types exhibited
significantly different global gene expression profiles. This
observation may be explained by a higher level of GRβ-D
isoform expression in TM 86 compared to TM 93 cells.
Alternatively, the fact that TM 86 and TM 93 cells were iso-
lated from an infant and an adult, respectively, may
account for the differences in gene expression patterns
between the two cell lines. It is also possible that inherent
differences between individuals may reflect differences in
gene expression profiles.
Table 3: Top 24 differentially regulated genes in response to DEX, FA, or TA treatment in TM 93 cell line. 
Gene Symbol Gene Name GenBank Accession Number DEX
FC
FA
FC
TA
FC
UPREGULATED
OCA2 oculocutaneous albinism II NM_000275 >100 98.0 >100
ANGPTL7 Angiopoietin-like 7 NM_021146 18.8 13.0 20.5
RGC32 Response gene to complement 32 NM_014059 18.8 11.0 19.9
LSP1 clone pp9372 unknown mRNA AF289610 NS 18.0 NS
SAA1 Serum amyloid A1 NM_000331 10.7 8.3 11.9
KCNB1 Potassium voltage-gated channel, Shab-related subfamily, 
member 1
NM_004975 9.3 5.2 11.3
ITGA10 Integrin, alpha 10 NM_003637 8.1 9.1 5.6
ANGPTL4 Angiopoietin-like 4 NM_139314 6.5 9.1 5.3
FKBP5 FK506 binding protein 5 NM_004117 5.9 6.8 5.8
PF4 platelet factor 4 (chemokine (C-X-C motif) ligand 4) NM_002619 5.2 6.5 4.4
ZBTB16 Zinc finger and BTB domain containing 16 NM_006006 5.4 4.9 5.5
KLF15 Kruppel-like factor 15 NM_014079 4.2 3.6 3.9
MYOC Myocilin, trabecular meshwork inducible glucocorticoid 
response
NM_000261 2.5 2.7 2.6
DOWNREGULATED
ENST00000344214 Unknown Unknown -5.6 -6.3 NS
KAL1 Kallmann syndrome 1 sequence NM_000216 -2.9 -3.0 -3.3
GABRB1 Gamma-aminobutyric acid (GABA) A receptor, beta 1 NM_000812 -2.5 -2.2 -2.6
AQP1 Aquaporin 1 (Colton blood group) NM_198098 -2.8 -3.2 -2.8
MXRA5 Matrix-remodelling associated 5 NM_015419 -3.9 -4.5 -4.5
PCDH19 Protocadherin 19 NM_020766 -2.9 -3.9 -3.3
PER3 Period homolog 3 (Drosophila) NM_016831 -2.8 -3.6 -3.8
CCRL1 Chemokine (C-C motif) receptor-like 1 NM_178445 -2.4 -2.5 -2.1
KIF4A Kinesin family member 4A NM_012310 -2.3 -2.2 -2.3
CXADR Coxsackie virus and adenovirus receptor NM_001338 -2.2 -1.8 -2.6
RASL11B RAS-like, family 11, member B NM_023940 -1.5 NS NS
FC: fold change; NS: not significant
The genes are listed according to their rank order fold-change.BMC Medical Genomics 2009, 2:58 http://www.biomedcentral.com/1755-8794/2/58
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To test the hypothesis that each GC generates subsets of
common and unique genes, we compared the global gene
expression profiles of two different TM cell types in
response to 24 hr treatment with a saturating GC concen-
tration. This is the first microarray study that compares the
effects of three clinically-relevant GCs at equimolar con-
centrations on the transcriptome of TM cells. Our study
shows that many genes commonly regulated by DEX, FA
and TA in TM 86 and TM 93 cells were also regulated by
DEX in published studies in primary TM cells [8-11].
These genes included MYOC, FKBP5, SAA1, SAA2,
ZBTB16, ANGPTL7, CXADR and PER3. The size of this
common subset of genes was steroid and cell-dependent,
and accounted for 16%-53% of all steroid-regulated genes
in TM86 cells and 33%-67% in TM93 cells.
Our results also showed that all three GCs regulated, in a
cell lineage-dependent manner, unique sets of genes
involved in a specific biological process or functional net-
work. The present study closely confirms recently pub-
The most prominently affected gene network in response to DEX in TM 86 cells Figure 5
The most prominently affected gene network in response to DEX in TM 86 cells. Network was classified as: RNA-
Post-Transcriptional Modification, Antigen Presentation, Immune cell Trafficking. Regulation of this network in TM 86 cells is com-
pared across treatment with DEX, FA or TA. Pathway contains RNA binding protein S1 (RNPS1), which occupies a central 
position in this network. Red: induction; green: repression; white: unaffected; color intensity correlates with fold change; 
number: fold change. The diagram was obtained from Ingenuity Pathway Analysis (Ingenuity® Systems).
Dex
TA
FA
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lished findings by Fan et al who demonstrated that TA and
DEX were capable of regulating common as well as
unique subsets of genes in TM cells [13]. The Fan et al
results showed that GC-regulated genes were associated
with multiple cell functions including acute-phase
response, cell adhesion, and cell cycle and growth. Similar
observations were obtained by Guo et al who showed that
different peroxisome proliferator-activated receptor α or γ
agonists were capable of generating common and unique
gene expression subsets in rodent primary hepatocytes
[38,39]. In the present study, gene function analysis
showed that in TM 86 cells, DEX significantly regulated a
network centered around the RNA binding protein S1 or
RNPS1, whereas FA significantly modulated a GR-
dependent network. In TM 93, DEX significantly affected
histone methyltransferase or SUZ12 network, whereas FA
regulated transcriptional repressor or JARID1B-based net-
work.
The functional and potential clinical significance of these
GC-dependent pharmacologic responses requires further
investigation. These responses are likely GC dose and
The most prominently affected gene network in response to FA in TM 93 cells Figure 6
The most prominently affected gene network in response to FA in TM 93 cells. Network was classified as: Cell Cycle, 
Cell-mediated Immune Response, Cellular Assembly and Organization. Regulation of this network in TM 93 cells is compared across 
treatment with DEX, FA or TA. Pathway contains jumonji, AT rich interactive domain 1B transcriptional repressor (JARID1B), 
which occupies a central position in this network. Red: induction; green: repression; white: unaffected; color intensity corre-
lates with fold change; number: fold change. The diagram was obtained from Ingenuity Pathway Analysis (Ingenuity® Systems).
FA Dex
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duration of exposure-dependent, and the results suggest a
very complex mechanism that is initiated by GC-GRα
interactions. For example, in addition to unique GC-
dependent gene subsets, specific genes such as OCA2 and
SLP1 were uniquely regulated by only one GC in one cell
line and regulated by all three GCs in the other cell line.
These observations suggest that in a specific cell line DEX,
FA, or TA generate a unique ligand-GR binding conforma-
tion, a unique GR-DNA binding domain conformation,
and the subsequent recruitment of distinct co-repressors
or co-activators. There may also be GC-dependent remod-
eling of the chromatin at the promoter of GR target genes.
Finally, the microarray results presented here further sup-
port the findings by Schaaf and Cidlowski that show GC
analogs with subtly different chemical structures are capa-
ble of generating unique patterns of GC-GRα nuclear dis-
tribution and mobility [21]. Our microarray data strongly
suggest that the GC-mediated GR nuclear distribution pat-
terns ultimately regulate common and unique subsets of
genes and presumably generate unique cellular responses.
The clinical impact of pharmacologically-distinct and
defined glucocorticoid agonists on inflammatory dis-
eases, including those of the eye, remains fertile ground
for future research.
Conclusion
A primary goal of this study was to determine if glucocor-
ticoids with similar potencies but subtly different chemi-
cal structures can generate both common and unique
subsets of genes in trabecular meshwork cells. This
hypothesis was proposed by Schaaf and Cidlowski from
studies showing that GC chemical structure directly influ-
enced GC/GRα nuclear distribution and mobility [21]. In
surrogate cell types, the GR binding affinity and GR-medi-
ated transactivation potencies for DEX, FA, or TA in are
similar (1 - 5 nM), and represent the aggregate affinity or
transactivation potency generated by multiple GRα and
GRβ isoforms. All four known GRα and GRβ translational
isoforms (A-D) were expressed in TM 86 and TM 93 cells.
The physiologic necessity and functional role for multiple
GRα isoforms in TM cells requires further study, however,
gene expression analysis revealed that 1,968 and 1,150
genes were regulated by DEX, FA, and TA in TM 86 and TM
93 cells, respectively. Many of these genes, including
MYOC, FKBP5, SAA1, ZBTB16 and ANGPTL7 were previ-
ously reported to be regulated by DEX or TA in primary
human TM cells. In addition to sets of genes shared by all
three GCs, each GC also regulated a unique subset of
genes in both TM cell lines. In TM 86, DEX significantly
regulated transcripts associated with RNA post-transcrip-
tional modifications, whereas FA and TA modulated genes
associated with lipid metabolism and cell morphology,
respectively. In TM 93 cells, DEX significantly regulated
genes related to histone methylation, whereas FA and TA
regulated genes related to cell cycle and cell adhesion,
respectively. These observations support the hypothesis
that DEX, FA, or TA are capable of generating common
and unique gene subsets via a unique conformation of the
GC-GRα complex, which ultimately results in the binding
of GRα to specific promoters on target genes. These
unique GC-mediated unique molecular effects are likely
time, dose, cell-type, and cell-lineage dependent.
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